Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Soft tissue sarcoma, child
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 29 for your search:
Start Over
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
Phase: Phase III
Type: Treatment
Age: 15 and over
Trial IDs: ALDOXORUBICIN-P3-STS-01, NCI-2014-00753, NCT02049905
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
Aerosolized Aldesleukin in Treating Patients with Lung Metastases
Phase: Phase II, Phase I
Type: Treatment
Age: 12 and over
Trial IDs: 2010-0700, NCI-2012-00788, NCT01590069
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 months to 21 years
Trial IDs: ABI-007-PST-001, NCI-2015-00737, NCT01962103
OKT3/Humanized 3F8 Bispecific Antibody-Activated T Lymphocytes, Aldesleukin, and Sargramostim in Treating Younger Patients with GD2-Positive Metastatic, Recurrent or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 moths to 29 years
Trial IDs: 2013-171, NCI-2014-01149, 1403012875, NCT02173093
Multitargeted Tyrosine Kinase Inhibitor PLX3397 in Treating Patients with Refractory Leukemias or Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
Sunitinib Malate or Cediranib Maleate in Treating Patients with Metastatic Soft Tissue Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 to 20
Trial IDs: 11-C-0200, NCI-2013-01496, 110200, P11836, P8875_A21PAMDREVW01, 8875, NCT01391962
Gemcitabine Hydrochloride with or without Pazopanib Hydrochloride in Treating Patients with Refractory Soft Tissue Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 and over
Trial IDs: 7943, NCI-2012-00052, NCT01532687
Gemcitabine Hydrochloride and Docetaxel or Pazopanib Hydrochloride in Treating Patients with Metastatic, Locally Advanced, or Locally Recurrent Soft Tissue Sarcoma
Phase: Phase II
Type: Treatment
Age: 18 to 90
Trial IDs: 101644, NCI-2012-00675, MUSC 101644, MUSC CTO 101644, PAZ115785, PZP115785, NCT01593748
Hypofractionated Stereotactic Radiation Therapy in Treating Younger Patients with Metastatic Sarcomas of Bony Sites
Phase: Phase II
Type: Treatment
Age: Greater than 3 to less than or equal to 40
Trial IDs: J1367, NCI-2013-02433, NA_00070109, NCT01763970
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Phase: Phase II
Type: Treatment
Age: 0 to 40
Trial IDs: J12106, NCI-2013-00702, CIR00008429, CIR00009228, NA_00076243, NA_00076243 / CIR00009228, NCT01804634
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 18
Trial IDs: 116731, NCI-2015-00058, NCT01956669
Iodine I 131 Monoclonal Antibody 8H9 in Treating Patients with Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 and over
Trial IDs: 09-090, NCI-2010-01242, NCT01099644
Donor Natural Killer Cells after Donor Peripheral Blood Stem Cell Transplant in Treating Younger Patients with Hematologic Malignancies
Phase: Phase I
Type: Treatment
Age: 4 to 35
Trial IDs: 11-C-0073, NCI-2013-01476, 110073, P09561, NCT01287104
A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma
Phase: Phase I
Type: Treatment
Age: 4 to 55
Trial IDs: ADP 04511, NCI-2015-00410, NCI-2013-01481, UPCC 04511, NCT01343043
Donor Cytotoxic T-Lymphocytes in Treating Patients With Relapsed Epstein-Barr Virus-Associated Diseases
Phase: Phase I
Type: Treatment
Age: Any age
Trial IDs: MALTED, NCI-2012-01079, H-28361, NCT01447056
Donor Hematopoietic Stem Cell Transplant in Treating Young Patients with Relapsed or Refractory Solid Tumors or Lymphomas
Phase: Phase I
Type: Treatment
Age: 2 to 21
Trial IDs: RADIANT, NCI-2012-00588, NCT01625351
Monoclonal Antibody 3F8 and Aldesleukin in Treating Patients with High-Risk Neuroblastoma and Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months and over
Trial IDs: 12-116, NCI-2012-01383, NCT01662804
Activated Natural Killer Cells with or without Recombinant Interleukin-15 in Treating Younger Patients with Refractory Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 25
Trial IDs: 13-C-0152, NCI-2013-01215, 09-25-0099, 130152, P9493_A06PAMDREVW01, 9493, NCT01875601
Heated Cisplatin following Surgery in Treating Younger Patients with Primary or Metastatic Pleural Malignancies
Phase: Phase I
Type: Treatment
Age: 3 to 21
Trial IDs: 2012-0657, NCI-2014-01101, NCI-2014-00510, NCT01998529
Simvastatin, Topotecan Hydrochloride, and Cyclophosphamide in Treating Younger Patients with Relapsed and/or Refractory Solid and CNS Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 29
Trial IDs: AFLACST1402, NCI-2015-00420, IRB00078790, NCT02390843
Proton Beam Radiation Therapy in Treating Younger Patients with Bone or Non-rhabdomyosarcoma Soft Tissue Sarcomas
Phase: No phase specified
Type: Treatment
Age: 30 and under
Trial IDs: 05-326, NCI-2012-00673, NCT00592293
Start Over